Citigroup
CYTK icon

Citigroup’s Cytokinetics CYTK Stock Holding History

Citigroup’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.69M Sell
56,000
-71,400
-56% -$4.54M ﹤0.01% 2205
2025
Q4 		$8.09M Buy
127,400
+101,900
+400% +$6.34M ﹤0.01% 1691
2025
Q3 		$1.4M Sell
25,500
-5,000
-16% -$206K ﹤0.01% 2948
2025
Q2 		$1.01M Sell
30,500
-30,000
-50% -$1.04M ﹤0.01% 3189
2025
Q1 		$2.43M Sell
60,500
-48,200
-44% -$2.22M ﹤0.01% 2528
2024
Q4 		$5.11M Sell
108,700
-96,700
-47% -$5.02M ﹤0.01% 1931
2024
Q3 		$10.8M Buy
205,400
+85,700
+72% +$4.78M 0.01% 1294
2024
Q2 		$6.49M Buy
+119,700
New +$7.23M ﹤0.01% 1476
2024
Q1 		– Sell
-180,900
Closed -$15.1M – 5675
2023
Q4 		$15.1M Buy
+180,900
New +$6.55M 0.01% 1011
2023
Q3 		– Sell
-55,000
Closed -$1.79M – 5691
2023
Q2 		$1.79M Sell
55,000
-29,400
-35% -$1.09M ﹤0.01% 2315
2023
Q1 		$2.97M Buy
84,400
+54,400
+181% +$2.22M ﹤0.01% 1766
2022
Q4 		$1.37M Buy
+30,000
New +$1.29M ﹤0.01% 2335
2022
Q3 		– Sell
-20,000
Closed -$786K – 5916
2022
Q2 		$786K Buy
+20,000
New +$805K ﹤0.01% 2870

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's CYTK Position: Q1 2026 in Review

Citigroup increased its Cytokinetics (CYTK) stake by 144% in Q1 2026, buying an estimated $9.35M and bringing the position to 249,243 shares worth $16.4M. The position accounts for 0.01% of the portfolio, ranked #1180.

Citigroup first reported a position in CYTK in Q2 2013 and has held it in 52 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Citigroup held 249,243 shares of Cytokinetics worth $16.4M as of Q1 2026.
  • Citigroup bought 147,142 Cytokinetics shares in Q1 2026, an estimated $9.35M.
  • Cytokinetics made up 0.01% of Citigroup's portfolio in Q1 2026, its #1180 holding.
  • Citigroup first reported a position in Cytokinetics in Q2 2013 and has held it in 52 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.